Table 7. Drug sensitivity and drug resistance in different drug groups of patients with community-acquired compared to nosocomial-acquired pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.

Abbreviations: CAP: community-acquired pneumonia; NAP: nosocomial-acquired pneumonia; MDR Pseudomonas: multidrug resistant Pseudomonas. Note: Significant P values are shown in bold.

		MDR Pseudomonas CAP (n = 27), NAP (n = 14)
Drug groups	Active substance	No. of tests of antibiotics on antibiogram		Sensitive		Intermediate		Resistant		ComparisonCAP + NAP
		CAP	NAP	CAP (%)	NAP (%)	CAP(%)	NAP (%)	CAP (%)	NAP (%)	P value
Penicillin	Piperacillin	27	14	15 (55.6)	6 (35.3)	0	0	12 (44.4)	8 (57.1)	0.741
Penicillin + β-lactamase inhibitors	Piperacillin + Tazobactam	27	14	15 (55.6)	7 (50.0)	0	0	12 (44.4)	7 (50.0)	0.947
Cephalosporins	Cefepime	27	14	20 (74.1)	7 (50.0)	0	0	7 (25.9)	7 (50.0)	0.304
	Ceftazidime	27	13	16 (59.3)	5 (38.5)	2 (7.4)	0	9 (33.3)	8 (61.5)	0.189
Carbapenems	Imipenem	27	14	11 (40.7)	7 (50.0)	1 (3.7)	0	15 (55.6)	7 (50.0)	0.687
	Meropenem	26	14	12 (46.2)	6 (42.9)	3 (11.5)	1 (7.1)	11 (42.3)	7 (50.0)	0.852
Gyrase inhibitors	Ciprofloxacin	27	13	8 (29.6)	4 (30.8)	0	1 (7.7)	19 (70.4)	8 (61.5)	0.336
	Levofloxacin	27	14	6 (22.2)	3 (21.4)	3 (11.1)	2 (14.3)	18 (66.7)	9 (64.3)	0.956
Aminoglycosides	Gentamicin	27	14	15 (55.6)	10 (71.4)	0	1 (7.1)	12 (44.4)	3 (21.4)	0.162
	Tobramycin	25	12	11 (44.0)	9 (75.0)	1 (4.0)	0	13 (52.0)	3 (27.3)	0.193
	Amikacin	22	11	14 (63.6)	10 (90.9)	2 (9.1)	0	6 (27.3)	1 (9.1)	0.236
Epoxide	Fosfomycin	7	7	2 (28.6)	1 (14.3)	5 (71.4)	0	0	6 (85.7)	0.0035
Polymyxin	Colistin	4	2	4 (100)	2 (100)	0	0	0	0	1.0